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Idiopathic pneumonia syndrome (IPS) is a diffuse, noninfectious lung injury that occurs acutely after allogeneic
hematopoietic cell transplantation (HCT). IPS-related mortality has been historically high (>50%) despite
treatment with systemic corticosteroids and supportive care measures. We have now examined the role of
tumor necrosis factor inhibition in a randomized, double-blind, placebo-controlled trial of corticosteroids with
etanercept or placebo. Thirty-four subjects (18 years) with IPS after HCT were randomized to receive meth-
ylprednisolone (2 mg/kg/day) plus etanercept (0.4 mg/kg twice weekly  4 weeks; n ¼ 16) or placebo (n ¼ 18).
No active infections and a pathogen-negative bronchoscopy were required at study entry. Response (alive, with
complete discontinuation of supplemental oxygen support) and overall survival were examined. This study,
originally planned to accrue 120 patients, was terminated prematurely due to slow accrual. In the limited
number of patients examined, there were no differences in response rates at day 28 of study. Ten of 16 patients
(62.5% [95% conﬁdence interval {CI}, 35.4% to 84.8%]) receiving etanercept and 12 of 18 patients (66.7% [95% CI,
41.0% to 86.7%]) receiving placebo met the day 28 response deﬁnition (P ¼ 1.00). The median survival was
170 days (95% CI, 11 to 362) with etanercept versus 64 days (95% CI, 26 to 209) with placebo (P ¼ .51). Among
responders, the median time to discontinuation of supplemental oxygenwas 9 days (etanercept) versus 7 days
(placebo). Therapy was well tolerated, with 1 toxicity-related death from infectious pneumonia in the placebo
arm. The treatment of IPS with corticosteroids in adult HCT recipients was associated with high early response
rates (>60%) comparedwithhistorical reports, with poor overall survival. The addition of etanercept did not lead
to further increases in response, although the sample size of this truncated trial preclude a deﬁnitive conclusion.
 2014 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.edgments on page 863.
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14.02.026INTRODUCTION
Pulmonary complications are common after hematopoi-
etic stem cell transplantation (HCT), occurring in nearlyerican Society for Blood and Marrow Transplantation.
Table 1
Diagnostic Criteria for IPS
1. Evidence of widespread alveolar injury
a. Bilateral, multilobar, or diffuse inﬁltrates on chest x-ray or
computed tomography.
b. SpO2  93% on room air, or supplemental O2 required to maintain
SpO2 > 93%.
2. Absence of active lower respiratory tract infection, based on
BAL assays
a. Gram stain, fungal stain, acid fast bacilli stain
b. Bacterial, fungal and mycobacterial cultures
c. Viral cultures for CMV, respiratory syncytial virus, parainﬂuenza,
adenovirus, inﬂuenza A and B
d. Pneumocystis jiroveci assay (direct ﬂuorescent antibody or
cytology)
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transplant-related deaths [1-4]. Within this context, idio-
pathic pneumonia syndrome (IPS) is an acute-onset, nonin-
fectious form of lung injury that develops early post-HCTand
is associated with high morbidity and mortality [5-11]. In
1993, a National Institutes of Health consensus panel pro-
posed a broad working deﬁnition of IPS to include wide-
spread alveolar injury in the absence of active lower
respiratory tract infection after HCT [5]. The deﬁnition was
updated in 2011 and further categorized the disease entities
falling under the deﬁnition of IPS by the primary anatomic
site of cellular damage, the interstitial tissue, vascular
endothelium, or airway epithelium [11]. The diagnosis of IPS
is made by the presence of multilobar inﬁltrates on chest
radiograph and clinical signs and symptoms of respiratory
distress (hypoxemia, dyspnea, rales) without infectious eti-
ology, as determined by a negative bronchoalveolar lavage
(BAL) or surgical lung biopsy. Infectious pneumonia, cardio-
genic shock, acute renal insufﬁciency and iatrogenic ﬂuid
overload must all be excluded to ensure the diagnosis of IPS.
The incidence of IPS ranges from 2% to 10%, depending on
patient age, degree of donorerecipient HLA match, graft
type, and conditioning intensity, with a median onset 14 to
42 days post-HCT. Historically, survival has been poor, with
mortality rates of 50% to 75% within 28 days of diagnosis [7-
11]. The intensity of the conditioning regimen impacts the
development of IPS, with a much lower incidence reported
after administration of a subablative conditioning regimen
[9,11]. The frequent association between IPS and acute graft-
versus-host disease (GVHD) also suggests an immunologic
mechanism for the syndrome, one driven by alloreactive
donor T cells, pulmonary macrophages, and mediated by
inﬂammatory cytokine production [11]. A role for tumor
necrosis factor (TNF)-a in the pathogenesis of the disorder
was initially suggested 15 years ago, with markedly elevated
levels of TNF-a and its soluble receptors observed within the
BAL ﬂuid of affected animals and patients [1,12-14]. Preclin-
ical models have shown that TNF-a contributes to the
pathogenesis of IPS, directly by causing endothelial cell
injury and apoptosis and indirectly by regulating inﬂam-
matory chemokine expression in the lung and subsequent
donor leukocyte inﬁltration during the early stages of dis-
ease. In addition, TNF neutralization reduces the severity of
IPS in murine models, further supporting a casual role for
TNF-a in the pathogenesis of the disorder [11,15].
Treatment options for IPS have historically combined
supportive care (supplemental oxygen, diuretics) with high-
dose systemic corticosteroids. More recently, the use of TNF
inhibitors was proposed, with potential beneﬁts noted in
single or limited institution studies [7,8,14]. In particular,
clinical trials combining a soluble TNF binding agent (eta-
nercept [Enbrel], Amgen Inc., Thousand Oaks, CA) with sys-
temic corticosteroids for the management of IPS reported
high response rates and improved overall survival [7,8,14].
Etanercept is a soluble dimeric binding protein consisting of
2 soluble p75 TNF receptors fused to the Fc portion of a type I
immunoglobulin molecule. The agent is U.S. Food and Drug
Administration approved in the management of juvenile,
rheumatoid, and psoriatic arthritis; plaque psoriasis; and
ankylosing spondylitis, conditions in which TNF-a is impli-
cated in the pathogenesis. In a follow-up to early phase
clinical studies, we conducted a multicenter, randomized,
double-blinded, phase III trial for the treatment of adults
with IPS through the Blood and Marrow Transplant Clinical
Trials Network (BMT CTN) and report the results herein.METHODS
Eligibility
Eligible patients were at least 18 years old, having received an allogeneic
bone marrow, cord blood, or peripheral blood stem cell transplant within
180 days of enrollment. There were no restrictions to study entry based on
underlying disease, donor source, degree of HLA match, or conditioning
regimen. Eligible patients were required to meet National Institutes of
Health Consensus criteria for IPS before study entry based on clinical ﬁnd-
ings, radiographic features, and BAL ﬂuid analysis (Table 1) [5,11]. Patients
with active infections, cytomegalovirus (CMV) viremia or CMV disease, a
prior history of active tuberculosis, or chronic active hepatitis B or C in-
fections were excluded from study entry. There was no restriction to entry
based on hematologic, renal, or hepatic dysfunction. Patients with pulmo-
nary edema secondary to iatrogenic ﬂuid overload or cardiac dysfunction, as
evidenced by echocardiogram or clinical ﬁndings, were ineligible. Patients
were excluded if they had received >2 mg/kg/day methylprednisolone
equivalent for >48 hours within 7 days of study entry or required me-
chanical ventilation for >168 continuous hours before study entry. Nonin-
fectious, diffuse alveolar hemorrhage is considered a subset of IPS, and
affected patients were eligible for study inclusion. The trial was registered at
Clinical Trials.gov as NCT00421174.
Study Design
All patients were required to undergo bronchoscopy with BAL at study
entry, with required observations speciﬁed in Table 1. Additional BAL ﬂuid
testing, including PCR assays for other bacterial, fungal, or viral or atypical
pathogens, and Pneumocystis jiroveci pneumoniawere allowed per physician
discretion. The presence of mixed oral ﬂora, “rare” Candida, or Penicillium on
the BAL did not exclude a patient from study, because such ﬁndings typically
reﬂect oral pharyngeal contamination. Transbronchial and surgical lung
biopsies were not required but were allowed per physician discretion. If a
BAL procedure had been obtained for any other purpose within 72 hours of
study enrollment, the procedure did not need to be repeated, provided that
no infectious pathogens were identiﬁed in that BAL ﬂuid.
After enrollment, patients were subsequently eligible for study
randomization and initiation of study therapy based on results of microbial
stains (Gram stain and fungal stains), completed on BAL ﬂuid, evenwhile the
remaining BAL studies were still pending. Patients whose initial BAL mi-
crobial stains identiﬁed a potential pathogen were ineligible for study
randomization. If at any point after initiation of study therapy BAL ﬂuid
analysis (cultures, stains, PCR assays) noted a likely pathogen, study therapy
was discontinued at that point and not reinstituted. PCR based assays were
not required, but if completed and positive, the patient was removed from
study therapy. A response assessment was made at the time of therapy
discontinuation and at subsequent study endpoints, and the patient was not
replaced on study.
Patients were randomized to receive either etanercept plus corticoste-
roids (arm A) or placebo plus corticosteroids (arm B). The study therapy was
subsequently initiated as long as BAL ﬂuid microbial studies remained
negative. The start of study therapy (etanercept or placebo) was deﬁned as
day 0. Corticosteroids were begun at 2 mg/kg/day methylprednisolone (or
corticosteroid equivalent), with dosing based on actual body weight. Pa-
tients already receiving corticosteroids at study entry remained on corti-
costeroids, with their dosing adjusted to 2 mg/kg/day methylprednisolone
equivalent on the day of enrollment. Intravenous corticosteroids were
required for the ﬁrst 3 days of study therapy, with oral dosing subsequently
allowed if the patient was able to tolerate oral intake. No corticosteroid taper
was allowed during the ﬁrst 7 days of study therapy, with subsequent taper
per physician discretion. A recommended steroid taper schedule through
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improved by day 7 but subsequently worsened after initiation of the corti-
costeroid taper were allowed to increase corticosteroid dosing to prior
dosing levels.
All patients received a total of 8 etanercept or placebo doses over a 24-
day period. Etanercept was administered at .4 mg/kg/dose (maximum dose
25 mg), with the initial etanercept dose given as a 30-minute i.v. infusion in
100 mL of .9 normal saline to expedite the attainment of maximal plasma
levels. The initial placebo dose was administered in a similar route and
dilution. Subsequent etanercept (or placebo) doses were given subcutane-
ously, twice weekly, for a total of 7 s.c. doses. All etanercept and placebo
doses were required to be at least 72 to 96 hours apart from the prior dose.
No premedication was administered. No dosage adjustments were required
based on renal or hepatic function. Both subjects and investigators were
blinded to study drug therapy, with no “unblinding” or crossover between
study arms allowed. Other immune-suppressive agents were continued
during study therapy, without dose adjustment, unless clinically indicated.
Patients received antimicrobial prophylaxis according to BMT CTN guide-
lines or local institutional practice.
If patients developed signs of sepsis syndrome, invasive fungal infections,
persistent bacteremia for >72 hours, or disseminated viral infections, study
therapy was discontinued and patients were removed from the trial and not
replaced on study. If a patient developed bacteremia, study therapy was held
until bacteremia resolved. If more than 2 doses of study drug were missed
because of persistent bacteremia despite antibiotic therapy for that organism,
study therapy was discontinued and the patient was removed from the trial
and not replaced. Similarly, if a patient developed CMV reactivation (by PCR or
antigenemia assay), study therapy was held until CMV titers fell below the
institutional cut-off for concern. If 2 or more doses of study drug were missed
because of persistently elevated CMV titers, despite directed antiviral therapy,
study drug was discontinued and the patient was removed from the trial and
not replaced. In each scenario, patients were still followed for outcome and
considered nonresponders provided they had not achieved the primary
response endpoint by that time point. Patients with asymptomatic viruria
were allowed to continue on therapy.
Statistical Analysis
The primary study endpoint was response to study therapy, with
response deﬁned as (1) survival to day 28 of study plus (2) discontinuation
of all supplemental oxygen support for >72 consecutive hours by day 28 of
study. The time to response was deﬁned as the ﬁrst of 3 consecutive days in
which all supplemental oxygen support had been discontinued. Patients
who subsequently required reinstitution of supplemental oxygen to achieve
a SpO2 > 93% were still deemed as responders, provided they had met the
response criteria above. Patients who failed to completely withdraw from
supplemental oxygen support or those who died from IPS or non-IPSere-
lated causes by day 28 of therapy were deﬁned as nonresponders. Patients
who came off study therapy per physician or patient discretion were
deemed nonresponders if they had not met the deﬁned response criteria by
the time of study withdrawal. Survival duration was deﬁned as the interval
from randomization to the date of death or last follow-up. Secondary study
endpoints included response to study therapy by day 56, overall mortality,
and time to discontinuation of supplemental oxygen support, measured in
the number of days from study entry.
The study was designed as a phase III, double-blind, randomized,
placebo-controlled, multicenter trial. Randomization between arms A and
B was performed in a 1:1 ratio, using random block sizes for the 2 arms.
A sample size of 60 patients per group was initially targeted, which would
provide 80% power to detect an increase in the response rate from 30% to
55%, after accounting for interim analyses for efﬁcacy and futility. Because
of slow accrual, the target sample size was amended to 30 patients per arm
to provide 80% power to detect an increase in the response rate from 30% to
69%, matching the effect size seen in the historical comparison [7]. The
study was closed early by the Data and Safety Monitoring Board because of
poor accrual, with 16 patients randomized to receive etanercept and
18 randomized to receive placebo. A post-hoc power analysis indicated
that this ﬁnal sample size had 80% power to detect an increase in the
response rate from 30% to 81%.
The primary intent-to-treat analysis of response to study therapy by day
28 post-randomization was conducted using Fisher’s exact test due to the
small sample sizes in the ﬁnal dataset. Exact (Clopper-Pearson) conﬁdence
intervals (CIs) for the response ratewere also obtained. Analyses of secondary
endpoints of response at day 56 were done in a similar fashion. Survival was
summarized using the Kaplan-Meier estimate. Time to discontinuation of
oxygen, acuteGVHDgrades II to IVor III to IV, chronicGVHD, and relapsewere
described using the cumulative incidence estimate, with death as a
competing risk. CIs for cumulative incidence or survival at speciﬁed time
points relied on exact Clopper-Pearson intervals, because the estimates
reduce to simple proportions without censoring present (1 year or earlier).Survival distributions were compared using the log-rank test, whereas cu-
mulative incidence curves were compared using Gray’s test [16]. Point-wise
comparisons of survival or cumulative incidence used Fisher’s exact test.
The protocol was approved by the National Heart, Lung, and Blood
Institute, local institutional review boards, and required BMT CTN sub-
committees. A Data and Safety Monitoring Board appointed by the National
Heart, Lung, and Blood Institute reviewed toxicity data and subsequent
analyses. Written informed consent was obtained from all patients (or legal
guardians) before study entry. A response assessment committee, blinded to
treatment assignment, reviewed all study data and determined the ﬁnal
assessment of eligibility, study deviations from planned therapy, and
response. All evaluations were reviewed by 3 independent reviewers.
RESULTS
Thirty-seven subjects were enrolled between September
2007 and August 2011 with 34 subjects assessable for
response assessment. In 2 subjects, BAL ﬂuid collected at
study entry was positive for infection, making them ineli-
gible for randomization. Neither individual received study
therapy. One patient withdrew informed consent at the time
of randomization. For the remaining 34 patients, 16 were
randomized to receive etanercept and 18 to placebo. Treat-
ment arms were balanced for baseline characteristics, except
for a higher frequency of transplantation for acute myelog-
enous leukemia on the placebo arm (50% versus 6%, P ¼ .02)
(Table 2). Approximately 40% of patients in both arms
received a nonmyeloablative conditioning regimen. Three
patients (19%) on the etanercept arm and six (33%) on the
placebo arm required mechanical ventilator support at study
entry (P¼ .45). Therewas no difference in the number of days
from transplant to study entry; the median time of study
entry was 17 days post-HCT in the etanercept arm versus
19 days post-transplant in the placebo arm (P ¼ .61). The
median FiO2 at study entry was 40% (range, 29% to 95%), with
no difference in the level of baseline supplemental oxygen
support between the 2 study arms. Only 8 of 16 patients
(50%) on the etanercept arm completed all 8 etanercept
doses, with 6 patients (37%) receiving  2 doses of eta-
nercept. Ten of 18 patients (56%) on the placebo arm received
all 8 placebo doses, with only 1 of 18 patients (6%)
receiving  2 placebo doses before study discontinuation.
Response and Survival
There was no difference in response between therapy
arms, at day 28 and day 56 (Table 3). Ten of 16 patients (62.5%
[95% CI, 35.4% to 84.8]) treated on the etanercept arm and 12
of 18 patients (66.7% [95% CI, 41.0% to 86.7%]) treated on the
placebo arm met the day 28 response deﬁnition (P ¼ 1.00).
Nine of 16 patients (56.3% [95% CI, 29.9% to 80.3%]) treated on
the etanercept arm and 9 of 18 patients (50.0% [95% CI, 26.0%
to 74.0%]) met the day 56 response deﬁnition (P ¼ .74). There
were no differences in the cumulative incidence of discon-
tinuation of supplemental oxygen between the etanercept
and placebo arms (P ¼ .69), with a median time to supple-
mental oxygen discontinuation of 9 days (etanercept) versus
7 days (placebo) among responders (Figure 1). There was no
difference in response between the 2 arms based on baseline
FiO2. Eight of 11 patients (73%) on the etanercept arm and 10
of 11 patients (91%) on the placebo arm responded to study
therapy when the baseline FiO2 was 40% (P ¼ .59). The in-
tensity of the transplant conditioning regimen did not affect
response, with responses seen in 10 of 14 patients (71%) who
developed IPS after a nonmyeloablative regimen versus 12 of
20 (60%) after a myeloablative regimen (P ¼ .72). There was
no difference in response by therapy arm (etanercept versus
placebo) in patients receiving nonmyeloablative transplants
(71% versus 71%, P ¼ 1.00). Nine of 10 patients (90%)
Figure 1. Time to discontinuation of supplemental oxygen support, arm A
(etanercept þ corticosteroids) versus arm B (placebo þ corticosteroids).
Table 2
Patient Demographics at Study Entry
Etanercept Placebo Total P
Total enrolled 18 19 37
Total eligible 16 18 34
Age, yr .89
Median 47.7 46.4 46.6
Mean 47.9 47.8 47.9
Range 22.9-70.1 21.8-68.8 21.8-70.1
Gender 1.00
Female 8 (50) 10 (55.6) 18 (52.9)
Male 8 (50) 8 (44.4) 16 (47.1)
Primary disease .02
AML 1 (6.3) 9 (50) 10 (29.4)
MDS 2 (12.5) 2 (11.1) 4 (11.8)
ALL 3 (18.8) 4 (22.2) 7 (20.6)
Lymphoma 3 (18.8) 0 (0) 3 (8.8)
Other 6 (37.5) 2 (11.1) 8 (23.5)
Performance status* .55
70-90 3 (18.8) 1 (5.6) 4 (11.7)
50-60 5 (31.3) 5 (27.8) 10 (29.4)
<50 5 (31.3) 10 (55.5) 15 (44.1)
Unknow 3 (18.8) 2 (11.1) 5 (14.7)
Conditioning regimen 1.00
Myeloablative 9 (56.2) 11 (61.1) 20 (58.8)
Nonmyeloablative 7 (43.8) 7 (38.9) 14 (41.2)
CMV statusy .86
Positive 8 (50) 10 (55.6) 18 (52.9)
Negative 8 (50) 7 (38.9) 15 (44.1)
Unknown 0 (0) 1 (5.6) 1 (2.9)
Total bilirubinz .93
Median 1.2 0.9 1.0
Range .2-18.9 .2e10.7 .2-18.9
Creatininex .88
Median 1.3 1.4 1.3
Range .6-2.5 .4-2.9 .4-2.9
Oxygen supportk .37
Nasal cannula 10 (62.5) 6 (33.3) 16 (47.1)
Face mask/Bipap 3 (18.8) 5 (27.8) 8 (23.5)
Mechanical ventilation 2 (12.5) 6 (33.3) 8 (23.5)
Unknown 1 (6.3) 1 (5.6) 2 (5.9)
AML indicates acute myelogenous leukemia; MDS, myelodysplastic syn-
drome; ALL, acute lymphoblastic leukemia; Bipap, biphasic positive airway
pressure.
Values are number of cases, with percents in parentheses, unless otherwise
noted.
* Karnofsky performance status at study entry.
y Subject CMV status at time of transplant.
z Serum total bilirubin (mg/dL) at study entry.
x Serum creatinine (mg/dL) at study entry.
k Method of supplemental oxygen support at study entry.
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criteria, with only 1 response among 6 patients (17%)
receiving  2 doses of etanercept before discontinuing study
therapy.Table 3
Response and Survival
Arm A
(n ¼ 16)
Arm B
(n ¼ 18)
P
Therapy Etanercept þ
steroids
Placebo þ
steroids
Median time to response, days 9 7 .69
Response rate, day 28, % 63 67 1.00
Response rate, day 56, % 56 50 .74
Corticosteroid dose,* day 28 0.57 0.49 .69
Median OS, days 170 64 .51
Day 28 OS, % 69 72 .82
Day 56 OS, % 63 61 .93
1-Year OS, % 23 17 .63
1-Year NRM, % 64 72 .65
OS indicates overall survival; NRM, nonrelapse mortality.
* Median corticosteroid dose (mg/kg/day, methylprednisolone equiva-
lent) on day 28 of study.Although the median survival for patients treated on the
etanercept arm was 170 days (95% CI, 11 to 362) compared
with 64 days (95% CI, 26 to 209) in the placebo arms, the
differences in survival were not signiﬁcantly different
(P ¼ .51) (Figure 2). Overall survival at 1 year post-therapy
was 23.4% (95% CI, 6.5% to 46.3%) and 16.7% (95% CI, 4.1% to
36.5%), respectively, for the etanercept and placebo arms (not
signiﬁcant). With a median follow-up of 23.7 months post-
randomization, 7 patients survived, 4 on the etanercept
arm (25%) and 3 on the placebo arm (17%). Ten deaths
occurred within the ﬁrst 28 days post-randomization, 5 on
each arm. For all patients, primary causes of death included
graft failure (n ¼ 1), relapse (n ¼ 4), acute GVHD (n ¼ 6),
chronic GVHD (n ¼ 1), progression of IPS (n ¼ 6), infection
(n ¼ 7), and organ failure (n ¼ 1). Six of the 7 infection-
related deaths occurred in the placebo arm, with 2 of the 7
from infectious pneumonitis, both in the placebo arm. TheFigure 2. Overall survival by treatment arm (months post-randomization).
Table 5
Infectious Complications*
Etanercept
(n ¼ 16)
Placebo
(n ¼ 18)
Total
(N ¼ 34)
Infections (patients)y 10 (63) 9 (50) 19 (56)
z
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viral (n ¼ 1), and fungal (n ¼ 1). There were no differences in
causes of death between the 2 arms (P ¼ .87). Four of 16
patients (25%) on the etanercept arm and 2 of 18 patients
(11%) on the placebo died from progression of IPS (P ¼ .36).Infections (events) 20 32 52
Bacterial 9 21 30
Viral 7 10 17
Fungal 4 2 6
Values are number of cases, with percents in parentheses.
* Infectious events in which a pathogen was documented. Excludes
febrile events without a deﬁned pathogen.
y Total number of patients who developed an infectious complication
between days 0 and 56.
z Total number of infectious events between days 0 and 56.Toxicity and Adverse Events
Ten patients on the etanercept arm (63%) and 18 patients
on the placebo arm (100%) reported at least 1 grade 3 to 5
toxicity between days 0 and 56 of therapy (P ¼ .006)
(Table 4). There were nonsigniﬁcant but higher incidences of
dyspnea, hypoxia, somnolence, hemorrhagic cystitis, muco-
sitis/stomatitis, and abnormal hepatic transaminases re-
ported between days 0 and 56 on the placebo arm, compared
with the etanercept arm. The most commonly reported
grades 3 to 5 events were hypoxia (56% frequency on the
etanercept arm and 89% on the placebo arm) and dyspnea
(50% on the etanercept arm and 83% on the placebo arm).
Three patients on the etanercept arm and 2 patients on the
placebo arm relapsed. The cumulative incidence of relapse at
1 year from study entry was 14.3% (95% CI, 1.8% to 42.8%)
versus 11.8% (95% CI, 1.5% to 36.4%) for the etanercept and
placebo arms respectively (P ¼ 1.00).
Infectious complications (pulmonary and nonpulmonary)
developed in 19 of 34 patients (56%) within 56 days of study
entry (Table 5). There was a slightly greater incidence of CMV
infections in the placebo arm compared with the etanercept
arm (33% versus 13%, P ¼ .23). Invasive aspergillus infections
developed in 4 patients, 2 per arm, including aspergillus
pneumonitis (2 cases), soft tissue infection (1 case), and
fungemia (1 case). Two additional fungal infections occurred,
both from Candida species, on the etanercept arm. Overall,
infectious pneumonia occurred in 4 patients on the eta-
nercept arm (25%) and 4 patients on the placebo arm (22%)
during the study period.Table 6
Corticosteroid Therapy for IPS: Historical Controls vs. Arm B, CTN 0403Graft-versus-Host Disease
Five patients (31.2% [95% CI, 11.0% to 58.7%]) on the
etanercept arm and 8 patients on the placebo arm (44.4%
[95% CI, 21.5% to 69.2%]) developed grades II to IV acute
GVHD within 56 days of study entry (P ¼ .50). The in-
cidences of grades III to IV GVHD were also similar, with 4
patients on the etanercept arm (25.0% [95% CI, 7.3% to
52.4%]) and 5 patients on the placebo arm (27.8% [95% CI,
9.7% to 53.5%]) developing grades III to IV GVHD during
study (P ¼ 1.00). The median time from diagnosis of IPS to
onset of acute GVHD was 7 days in both the etanercept and
placebo arms. Two patients on the etanercept arm devel-
oped chronic GVHD within 1 year from study entry (12.5%
[95% CI, 1.6% to 38.4%]), whereas no patients on the placebo
arm developed chronic GVHD within that time period (0%
[95% CI, 0 to 18.5%]; P ¼ .21).Table 4
Noninfectious Complications: Grades 3-5 Events
Toxicity Etanercept
(n ¼ 16)
Placebo
(n ¼ 18)
Total
(N ¼ 34)
Renal 4 (25) 3 (17) 7 (21)
Hepatic 7 (44) 14 (78) 21 (62)
Cardiac 1 (6) 2 (11) 3 (9)
CNS 2 (13) 6 (33) 8 (24)
CNS indicates central nervous system.
Values are number of cases, with percents in parentheses.Corticosteroid Requirements
All 34 patients were treated with systemic corticosteroids
with methylprednisolone at 2 mg/kg/day on day 0, with ta-
per allowed after day 7. There was no difference in cortico-
steroid requirement between the etanercept and placebo
arms, at both day 14 and day 28 of study. By day 14, the
median corticosteroid dose was .94 mg/kg/day (range, .56 to
1.92) for the etanercept arm versus 1.00 mg/kg/day (range,
.25 to 2.21) for the placebo arm (P ¼ .96). By day 28, the
median corticosteroid dose was .57 mg/kg/day (range, 0 to
2.0) and .49 mg/kg/day (range, .03 to 1.04) for the etanercept
and placebo arms, respectively (P ¼ .69).
DISCUSSION
The current study was designed to examine the impact of
a soluble TNF binding protein, etanercept, when given in
conjunction with systemic corticosteroids in the manage-
ment of IPS in adult HCT recipients. Although BMT CTN0403
fell far short of anticipated accrual, with inadequate power
and sample size to make deﬁnitive conclusions, speciﬁc as-
pects of the protocol are still valuable for consideration.
Historically, early response and overall survival have been
poor (<50%) when IPS was treated with systemic cortico-
steroids plus supportive care measures alone. In the past
decade, signiﬁcant improvements in day 28 survival (>70%)
were reported in 2 limited institution studies combining
etanercept with systemic corticosteroids [7,8]. In the current
study, the day 28 response (67%) and survival (72%) noted in
the corticosteroid (plus placebo) arm greatly exceeded his-
torical reports using corticosteroids as primary management
(Table 6), whereas 1-year survival remained poor (16.7%).
Has IPS changed over the past 2 decades? The statistical
plan for BMT CTN0403 was based on historical data from the
University of Michigan Medical Center (1996 to 2002) in
which IPS occurred in 9.0% of transplants, a median 15 daysMichigan [7]
(N ¼ 59)
Penn [8]
(N ¼ 22)
CTN 0403 Arm B
(n ¼ 18)
Therapy Steroids Steroids Steroids þ
placebo
Median time to
response, days
14 16 7
Response rate, % 30 18 67
Median OS, days 15 NS 64
Day 28 OS, % 33 36 72
OS,* % 6 9 17
OS indicates overall survival.
* OS at day 100 for the Michigan cohort and at 1 year for Penn and CTN
0403 Arm B cohorts.
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with corticosteroids plus supportive care. This incidence of
IPS was supported by data from the Center for International
Blood and Marrow Transplant Research during a similar time
period. However, signiﬁcant differences in supportive care
practices, conditioning regimen intensity, the frequency of
performing BAL, and the ability to isolate pathogens on a BAL
have occurred over the past decade. With molecular-based
assays for a wide variety of pathogens now in common use,
the potential exists that IPS identiﬁed in the 1990s may not
be identiﬁed as such now. Additionally, the use of reduced-
intensity conditioning has increased signiﬁcantly over this
same time period, with 41.1% of patients on BMT CTN0403
treated after receiving reduced-intensity regimen. By com-
parison, none of the historical control subjects in the Uni-
versity of Michigan IPS database received reduced-intensity
conditioning. The intensity of the conditioning regimen has
been postulated to impact the incidence of IPS, with signif-
icantly lower rates of IPS seen with reduced intensity [9].
Could the intensity of the conditioning regimen also impact
response to therapy once IPS develops? As such, are there
subjects for whom corticosteroids alone are sufﬁcient to
treat IPS without the addition of a TNF inhibitor (eta-
nercept)? Conversely, are their subjects with IPS who are
more likely to beneﬁt from the addition of TNF-a inhibition?
Although our trial was not designed to answer either of
these questions, the expression of TNF-a and its surrogate
markers, stratiﬁed by regimen intensity and IPS severity, is
currently being examined on BAL ﬂuid and plasma of study
subjects and may help to elucidate these issues. Moreover,
we recently identiﬁed a set of IPS-associated proteins that
revealed distinct similarities between IPS in humans and
animal models and could predict at the time of HCT
patients who progressed to IPS and who respond to eta-
nercept therapy [17]. Patients predisposed to over-express
TNF-a in response to immunologic stress (ie, high TNF-a
secretors) may be more likely to beneﬁt from strategies
that neutralize this protein. Current strategies to assay
TNF-a levels in real time from affected patients is now
being examined at various centers and may ultimately be
beneﬁcial in optimizing therapy.
BMT CTN0403 was initially designed to enroll 120 pa-
tients, 60 per arm. Accrual fell far short of projected expec-
tations, with only 34 (28%) of a targeted 120 subjects
enrolled. Given slow accrual, the statistical design was sub-
sequently amended to enroll 60 patients, 30 per arm. Other
amendments to increase accrual included extending the
eligibility from IPS developing within 120 days to IPS
developing within 180 days post-transplant and modifying
enrollment criteria so that bronchoscopy and BAL were no
longer required for patients developing IPS within 30 days
post-transplant. On-study surveys were tracked during the
study course, investigating factors that impacted potential
accrual. Reported factors included (1) investigator bias (pro
or con) regarding the test agent (etanercept), (2) investigator
reluctance to perform a BAL in critically ill patients, and,
most importantly, (3) a much lower incidence of IPS than
originally anticipated. The critical nature of the patient
populationwas evident, with 8 of 34 patients (24%) requiring
mechanical ventilation at baseline and an additional 6 pa-
tients requiring > 40% supplemental oxygen support (non-
ventilated) at baseline. Importantly, nearly 40% of patients
treated on the etanercept arm discontinued study therapy
after receiving 2 (or fewer) doses of etanercept, in several
cases because of investigator reluctance to continue“blinded” therapy. Response rates were poor in this group of
patients, compared with those receiving > 2 doses of eta-
nercept. Ultimately, a patient was more likely to continue
therapy if he or shewas were stable or improving early in the
treatment course, rather than not improving. This study
highlights both the difﬁculties in performing phase III trials
in critically ill patients and the merits of including a
contemporaneous control group in a clinical trial.
In summary, the treatment of IPS with corticosteroids
in adult HCT recipients was associated with high early
response rates (>60%) when compared with historical re-
ports. The addition of etanercept did not lead to further
increases in response, although the small sample size of
this truncated trial precludes a deﬁnitive conclusion. Eta-
nercept administration was not associated with increased
toxicity, incidence of opportunistic infection, or risk of
relapse when compared with placebo controls. Although
early response rates were high in both arms, long-term
outcomes remain unacceptably poor in this patient pop-
ulation, underscoring the continued need for novel ther-
apeutic options.ACKNOWLEDGMENTS
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